Sugi Predict

Sugi Predict / Targets / STK4

STK4

Serine/threonine-protein kinase 4 · Q13043 · STK4 on Sugi Atlas →

19,175 patent compounds predicted against STK4, 13,303 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1017694 SCHEMBL1017694 0.50 11/20
SCHEMBL336612 SCHEMBL336612 0.52 8/20
SCHEMBL938318 SCHEMBL938318 0.52 6/20
SCHEMBL938091 SCHEMBL938091 0.50 6/20
Bromide Bromide (SCHEMBL869439) 0.68 5/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL868416) 0.65 5/20
SCHEMBL371886 SCHEMBL371886 0.60 3/20
SCHEMBL372007 SCHEMBL372007 0.56 3/20
SCHEMBL372225 SCHEMBL372225 0.56 3/20
SCHEMBL371939 SCHEMBL371939 0.55 3/20
SCHEMBL372271 SCHEMBL372271 0.55 3/20
SCHEMBL1001928 SCHEMBL1001928 0.45 3/20
SCHEMBL1003089 SCHEMBL1003089 0.43 3/20
SCHEMBL1051669 SCHEMBL1051669 0.41 3/20
Cerdulatinib Cerdulatinib (SCHEMBL736734) 1.00 2/20
SCHEMBL371758 SCHEMBL371758 0.87 2/20
SCHEMBL737349 SCHEMBL737349 0.85 2/20
SCHEMBL736830 SCHEMBL736830 0.83 2/20
SCHEMBL371897 SCHEMBL371897 0.82 2/20
SCHEMBL738226 SCHEMBL738226 0.79 2/20

Clinical trials — most relevant to STK4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions PHASE4UNKNOWN
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER PHASE2/PHASE3RECRUITING
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus PHASE2COMPLETED
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations PHASE2COMPLETED
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease PHASE2COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer PHASE2COMPLETED
Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma PHASE2UNKNOWN
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours PHASE1/PHASE2RECRUITING
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). PHASE1ACTIVE_NOT_RECRUITING
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON) PHASE1COMPLETED
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors PHASE1RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Exercise in Type 1 Diabetes Mellitus nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Exercise Effects on Cardiometabolic Health and Sestrin-2 in Hypertensive Obese Women nanNOT_YET_RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a STK4 binder may also engage these)

ProteinNameSimilarity
A4K2M3 — 1.000 A4K2M3 →
A4K2Y1 — 1.000 A4K2Y1 →
A4K2W5 — 1.000 A4K2W5 →
A4K2T0 — 1.000 A4K2T0 →
A4K2P5 — 1.000 A4K2P5 →
A4K2Q5 — 1.000 A4K2Q5 →
Q5E9L6 — 1.000 Q5E9L6 →
Q9JI11 — 1.000 Q9JI11 →
Q5ZJK4 — 1.000 Q5ZJK4 →
Q802A6 — 1.000 Q802A6 →
A4K2S1 — 1.000 A4K2S1 →
STK3 Serine/threonine-protein kinase 3 1.000 landscape →
Q9JI10 — 1.000 Q9JI10 →
Q6IP06 — 1.000 Q6IP06 →
Q7ZUQ3 — 1.000 Q7ZUQ3 →
Q9NB31 — 1.000 Q9NB31 →
O54748 — 1.000 O54748 →
Q6PA14 — 0.997 Q6PA14 →
PAK3 Serine/threonine-protein kinase PAK 3 0.996 landscape →
Q6P3Q4 — 0.995 Q6P3Q4 →
P35465 — 0.994 P35465 →
A8XJW8 — 0.994 A8XJW8 →
Q08E52 — 0.993 Q08E52 →
Q7YQL4 — 0.993 Q7YQL4 →
PAK2 Serine/threonine-protein kinase PAK 2 0.993 landscape →
Q8AXB4 — 0.992 Q8AXB4 →
O61125 — 0.992 O61125 →
O88643 — 0.992 O88643 →
Q8CIN4 — 0.991 Q8CIN4 →
Q7YQL3 — 0.990 Q7YQL3 →